Page last updated: 2024-12-08

ro 03-7894

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ro 03-7894: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID194324
MeSH IDM0069958

Synonyms (6)

Synonym
ro 03-7894
69662-71-1
1-(5-chloroacetylaminobenzofuran-2-yl)-2-isopropylaminoethanol
acetamide, 2-chloro-n-(2-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-5-benzofuranyl)-
2-chloro-n-(2-{1-hydroxy-2-[(propan-2-yl)amino]ethyl}-1-benzofuran-5-yl)acetamide
DTXSID90869007

Research Excerpts

Dosage Studied

Cumulative dose-response curves to the agonists were constructed before and after incubation with and washout of the irreversible beta-adrenoreceptor antagonist, Ro 03-7894 1-(5-chloracetylaminobenzfuran-2-yl)-2-isopropylaminoethanol. The slopes of the dose- response curves to isoprenaline were depressed for up to 24 h by Ro 03 -7894 but this was not so with Ro 3-5255.

ExcerptRelevanceReference
" The slopes of the dose-response curves to isoprenaline were depressed for up to 24 h by Ro 03-7894 but this was not so with Ro 03-5255."( The in vivo examination of the irreversible beta-adrenoceptor antagonist Ro 03-7894 on cardiac rate and contractility.
Broadley, KJ; Burden, DT; Natoff, IL; Nicholson, CD,
)
0.58
" Three weeks of pretreatment with 6-OHDA resulted in leftwards shifts of the dose-response curves for the positive chronotropic and inotropic responses of right and left atria to isoprenaline."( Cardiac postjunctional supersensitivity to beta-agonists after chronic chemical sympathectomy with 6-hydroxydopamine.
Broadley, KJ; Chess-Williams, RG; Culling, W; Grassby, PF; Penny, W; Sheridan, DJ, 1985
)
0.27
" Cumulative dose-response curves to the agonists were constructed before and after incubation with and washout of the irreversible beta-adrenoreceptor antagonist, Ro 03-7894 1-(5-chloracetylaminobenzfuran-2-yl)-2-isopropylaminoethanol)."( Dissociation constants of isoprenaline and orciprenaline and their relative efficacies on guinea-pig isolated atria determined by use of an irreversible beta-adrenoceptor antagonist.
Broadley, KJ; Nicholson, CD, 1981
)
0.46
" The maximum of the dose-response curve to isoprenaline, constructed after incubation with Ro 03-7894 and a 3 hr bath-washout, was depressed by 89."( Comparison of the apparent irreversible beta-adrenoceptor antagonist Ro 03-7894 with propranolol in cardiac ventricular muscle by pharmacological and radioligand binding techniques.
Broadley, KJ; Rankin, A, 1982
)
0.72
" At the lower temperature, supersensitivity to orciprenaline and isoprenaline was exhibited as shifts of the dose-response curves to the left and significant reductions in EC50 values."( Temperature-induced changes in dissociation constants (KA) of agonists at cardiac beta-adrenoceptors determined by use of the irreversible antagonist Ro 03-7894.
Broadley, KJ; Williams, RG, 1983
)
0.46
"6 mM) produced a non-parallel shift to the right of dose-response curves to (-)-isoprenaline in K+ depolarized uterine preparations from the guinea-pig."( Is Ro 03-7894 an irreversible antagonist at beta-adrenoceptor sites?
Krstew, E; Malta, E; McPherson, GA; Molenaar, P; Raper, C, 1984
)
0.89
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.96 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.96)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]